ReportWire

Tag: Hedge Fund Holdings

  • Harvest Fund Management Co. Ltd Has $426,000 Stock Holdings in Honeywell International Inc. (NASDAQ:HON)

    Harvest Fund Management Co. Ltd Has $426,000 Stock Holdings in Honeywell International Inc. (NASDAQ:HON)

    [ad_1]

    Harvest Fund Management Co. Ltd raised its stake in shares of Honeywell International Inc. (NASDAQ:HON – Get Rating) by 68.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,002 shares of the conglomerate’s stock after purchasing an additional 812 shares during the quarter. Harvest Fund Management Co. Ltd’s holdings in Honeywell International were worth $426,000 as of its most recent filing with the Securities and Exchange Commission.

    Other hedge funds have also modified their holdings of the company. Bellwether Advisors LLC increased its position in Honeywell International by 14.3% during the 3rd quarter. Bellwether Advisors LLC now owns 383 shares of the conglomerate’s stock worth $63,000 after purchasing an additional 48 shares in the last quarter. Key Financial Inc boosted its holdings in shares of Honeywell International by 3.8% during the 3rd quarter. Key Financial Inc now owns 1,340 shares of the conglomerate’s stock valued at $224,000 after acquiring an additional 49 shares in the last quarter. S&CO Inc. increased its holdings in Honeywell International by 3.4% in the 3rd quarter. S&CO Inc. now owns 1,522 shares of the conglomerate’s stock worth $254,000 after purchasing an additional 50 shares in the last quarter. Vantage Financial Partners Ltd. Inc. raised its position in Honeywell International by 0.8% in the third quarter. Vantage Financial Partners Ltd. Inc. now owns 6,125 shares of the conglomerate’s stock valued at $1,023,000 after purchasing an additional 50 shares during the last quarter. Finally, Lcnb Corp boosted its stake in shares of Honeywell International by 1.0% during the third quarter. Lcnb Corp now owns 5,052 shares of the conglomerate’s stock valued at $844,000 after purchasing an additional 50 shares in the last quarter. 74.30% of the stock is owned by institutional investors and hedge funds.

    Analyst Upgrades and Downgrades

    HON has been the subject of a number of research reports. JPMorgan Chase & Co. raised their price objective on shares of Honeywell International from $205.00 to $215.00 and gave the company an “overweight” rating in a report on Friday, February 3rd. Morgan Stanley lifted their price target on shares of Honeywell International from $209.00 to $213.00 and gave the stock an “equal weight” rating in a report on Friday, February 3rd. HSBC increased their price objective on Honeywell International from $190.00 to $205.00 and gave the company a “hold” rating in a report on Tuesday, February 14th. Deutsche Bank Aktiengesellschaft cut their target price on Honeywell International from $235.00 to $228.00 and set a “buy” rating on the stock in a report on Wednesday, April 12th. Finally, Royal Bank of Canada raised their target price on Honeywell International from $204.00 to $208.00 and gave the stock a “sector perform” rating in a research note on Wednesday, March 29th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Honeywell International has an average rating of “Hold” and an average price target of $214.44.

    Honeywell International Stock Up 0.4 %

    Honeywell International stock opened at $196.78 on Tuesday. The company has a debt-to-equity ratio of 0.87, a quick ratio of 0.98 and a current ratio of 1.25. The stock has a market cap of $131.00 billion, a PE ratio of 27.07, a price-to-earnings-growth ratio of 2.41 and a beta of 1.09. Honeywell International Inc. has a fifty-two week low of $166.63 and a fifty-two week high of $220.96. The firm’s 50-day simple moving average is $191.10 and its 200 day simple moving average is $201.86.

    Honeywell International (NASDAQ:HON – Get Rating) last issued its quarterly earnings results on Thursday, February 2nd. The conglomerate reported $2.52 EPS for the quarter, beating analysts’ consensus estimates of $2.51 by $0.01. The company had revenue of $9.19 billion during the quarter, compared to the consensus estimate of $9.26 billion. Honeywell International had a return on equity of 32.89% and a net margin of 14.00%. Honeywell International’s revenue was up 6.1% on a year-over-year basis. During the same period last year, the business posted $2.09 earnings per share. Research analysts predict that Honeywell International Inc. will post 9.03 EPS for the current fiscal year.

    Honeywell International Dividend Announcement

    The business also recently declared a quarterly dividend, which will be paid on Friday, June 2nd. Investors of record on Friday, May 12th will be issued a $1.03 dividend. This represents a $4.12 dividend on an annualized basis and a dividend yield of 2.09%. Honeywell International’s dividend payout ratio (DPR) is currently 56.67%.

    Honeywell International Profile

    (Get Rating)

    Honeywell International, Inc is a software industrial company, which offers industry specific solutions to aerospace and automotive products and services. It specializes in turbochargers control, sensing and security technologies for buildings and homes, specialty chemicals, electronic and advanced materials, process technology for refining and petrochemicals, and energy efficient products and solutions for homes, business, and transportation.

    Recommended Stories

    Institutional Ownership by Quarter for Honeywell International (NASDAQ:HON)

    Receive News & Ratings for Honeywell International Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Honeywell International and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Goldstein Advisors LLC Makes New $836,000 Investment in Raytheon Technologies Co. (NYSE:RTX)

    Goldstein Advisors LLC Makes New $836,000 Investment in Raytheon Technologies Co. (NYSE:RTX)

    [ad_1]

    Goldstein Advisors LLC acquired a new stake in Raytheon Technologies Co. (NYSE:RTX – Get Rating) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 8,282 shares of the company’s stock, valued at approximately $836,000.

    Other hedge funds also recently modified their holdings of the company. Vanguard Group Inc. increased its position in Raytheon Technologies by 0.6% during the third quarter. Vanguard Group Inc. now owns 123,174,905 shares of the company’s stock worth $10,083,098,000 after acquiring an additional 760,968 shares during the period. Capital World Investors increased its stake in Raytheon Technologies by 32.8% during the 1st quarter. Capital World Investors now owns 9,130,557 shares of the company’s stock worth $904,564,000 after acquiring an additional 2,256,475 shares during the period. Alliancebernstein L.P. raised its holdings in Raytheon Technologies by 0.5% in the 3rd quarter. Alliancebernstein L.P. now owns 9,102,540 shares of the company’s stock valued at $745,134,000 after acquiring an additional 42,111 shares in the last quarter. Fisher Asset Management LLC lifted its position in shares of Raytheon Technologies by 2.8% during the 4th quarter. Fisher Asset Management LLC now owns 8,812,201 shares of the company’s stock valued at $889,327,000 after acquiring an additional 237,021 shares during the period. Finally, Royal Bank of Canada increased its position in shares of Raytheon Technologies by 4.7% in the first quarter. Royal Bank of Canada now owns 6,575,791 shares of the company’s stock worth $651,464,000 after purchasing an additional 294,366 shares during the period. Institutional investors and hedge funds own 78.83% of the company’s stock.

    Raytheon Technologies Stock Performance

    Shares of RTX opened at $102.25 on Monday. Raytheon Technologies Co. has a 1 year low of $80.27 and a 1 year high of $108.84. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.09 and a quick ratio of 0.81. The stock’s fifty day moving average price is $99.23 and its two-hundred day moving average price is $97.13. The firm has a market cap of $149.61 billion, a PE ratio of 29.21, a PEG ratio of 2.44 and a beta of 0.99.

    Raytheon Technologies (NYSE:RTX – Get Rating) last released its quarterly earnings data on Tuesday, January 24th. The company reported $1.27 EPS for the quarter, topping the consensus estimate of $1.24 by $0.03. Raytheon Technologies had a net margin of 7.75% and a return on equity of 9.73%. The company had revenue of $18.09 billion during the quarter, compared to the consensus estimate of $18.16 billion. During the same period last year, the firm earned $1.08 EPS. Raytheon Technologies’s revenue for the quarter was up 6.2% on a year-over-year basis. On average, equities research analysts forecast that Raytheon Technologies Co. will post 5.01 EPS for the current year.

    Raytheon Technologies Dividend Announcement

    The company also recently declared a quarterly dividend, which was paid on Thursday, March 23rd. Shareholders of record on Friday, February 24th were paid a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 2.15%. The ex-dividend date was Thursday, February 23rd. Raytheon Technologies’s dividend payout ratio (DPR) is currently 62.86%.

    Wall Street Analysts Forecast Growth

    Several research firms recently weighed in on RTX. Credit Suisse Group upped their price objective on shares of Raytheon Technologies from $103.00 to $106.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 25th. Royal Bank of Canada raised their price objective on Raytheon Technologies from $107.00 to $110.00 in a report on Wednesday, January 25th. Wells Fargo & Company raised their price target on shares of Raytheon Technologies from $96.00 to $107.00 and gave the company an “equal weight” rating in a research note on Wednesday, January 25th. The Goldman Sachs Group lowered shares of Raytheon Technologies from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $115.00 to $105.00 in a report on Friday, January 13th. Finally, Morgan Stanley decreased their target price on Raytheon Technologies from $119.00 to $115.00 and set an “overweight” rating for the company in a research note on Thursday, January 19th. Five research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $111.50.

    Insiders Place Their Bets

    In other news, VP Amy L. Johnson sold 3,622 shares of the business’s stock in a transaction that occurred on Tuesday, February 28th. The shares were sold at an average price of $98.55, for a total value of $356,948.10. Following the completion of the sale, the vice president now directly owns 4,061 shares in the company, valued at approximately $400,211.55. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.11% of the stock is owned by insiders.

    About Raytheon Technologies

    (Get Rating)

    Raytheon Technologies Corp. is an aerospace and defense company, which engages in the provision of aerospace and defense systems and services for commercial, military, and government customers. It operates through the following segments: Collins Aerospace Systems (Collins), Pratt and Whitney, Raytheon Intelligence and Space (RIS), and Raytheon Missiles and Defense (RMD).

    See Also

    Want to see what other hedge funds are holding RTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Raytheon Technologies Co. (NYSE:RTX – Get Rating).

    Institutional Ownership by Quarter for Raytheon Technologies (NYSE:RTX)

    Receive News & Ratings for Raytheon Technologies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Raytheon Technologies and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • ProShare Advisors LLC Sells 2,143 Shares of HCA Healthcare, Inc. (NYSE:HCA)

    ProShare Advisors LLC Sells 2,143 Shares of HCA Healthcare, Inc. (NYSE:HCA)

    [ad_1]

    ProShare Advisors LLC decreased its holdings in shares of HCA Healthcare, Inc. (NYSE:HCA – Get Rating) by 6.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 30,690 shares of the company’s stock after selling 2,143 shares during the period. ProShare Advisors LLC’s holdings in HCA Healthcare were worth $7,364,000 as of its most recent SEC filing.

    Other large investors also recently added to or reduced their stakes in the company. Ellevest Inc. boosted its stake in HCA Healthcare by 13.4% during the third quarter. Ellevest Inc. now owns 1,043 shares of the company’s stock valued at $192,000 after buying an additional 123 shares during the period. Daymark Wealth Partners LLC purchased a new stake in HCA Healthcare during the fourth quarter valued at about $705,000. Handelsbanken Fonder AB raised its position in HCA Healthcare by 2.0% during the third quarter. Handelsbanken Fonder AB now owns 36,950 shares of the company’s stock valued at $6,791,000 after purchasing an additional 708 shares in the last quarter. Greenleaf Trust raised its position in HCA Healthcare by 11.5% during the third quarter. Greenleaf Trust now owns 5,344 shares of the company’s stock valued at $982,000 after purchasing an additional 551 shares in the last quarter. Finally, Keybank National Association OH purchased a new stake in HCA Healthcare during the fourth quarter valued at about $495,000. Institutional investors own 64.60% of the company’s stock.

    HCA Healthcare Stock Up 3.9 %

    Shares of HCA opened at $281.21 on Friday. The business’s 50 day moving average price is $258.39 and its 200-day moving average price is $242.29. HCA Healthcare, Inc. has a 52 week low of $164.47 and a 52 week high of $294.02. The stock has a market cap of $77.89 billion, a P/E ratio of 14.62, a P/E/G ratio of 1.94 and a beta of 1.64.

    HCA Healthcare (NYSE:HCA – Get Rating) last issued its quarterly earnings results on Friday, January 27th. The company reported $4.64 EPS for the quarter, missing analysts’ consensus estimates of $4.79 by ($0.15). HCA Healthcare had a negative return on equity of 1,260.96% and a net margin of 9.37%. The company had revenue of $15.50 billion during the quarter, compared to the consensus estimate of $15.51 billion. On average, equities analysts anticipate that HCA Healthcare, Inc. will post 17.18 EPS for the current year.

    HCA Healthcare Dividend Announcement

    The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 30th. Investors of record on Friday, June 16th will be issued a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 0.85%. HCA Healthcare’s payout ratio is currently 12.48%.

    HCA Healthcare announced that its Board of Directors has authorized a share repurchase plan on Friday, January 27th that authorizes the company to buyback $3.00 billion in shares. This buyback authorization authorizes the company to purchase up to 4.2% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s management believes its shares are undervalued.

    Wall Street Analysts Forecast Growth

    HCA has been the topic of a number of research reports. UBS Group raised their price target on HCA Healthcare from $237.00 to $296.00 and gave the company a “buy” rating in a research report on Friday, January 13th. JPMorgan Chase & Co. lifted their price objective on HCA Healthcare from $257.00 to $283.00 and gave the stock a “neutral” rating in a report on Wednesday. Mizuho lifted their price objective on HCA Healthcare from $279.00 to $298.00 and gave the stock a “buy” rating in a report on Tuesday, April 11th. Truist Financial lifted their price objective on HCA Healthcare from $270.00 to $290.00 and gave the stock a “buy” rating in a report on Monday, January 30th. Finally, Cantor Fitzgerald began coverage on HCA Healthcare in a report on Thursday. They issued an “overweight” rating and a $304.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, HCA Healthcare has a consensus rating of “Moderate Buy” and an average price target of $272.87.

    Insider Buying and Selling

    In related news, CFO Bill B. Rutherford sold 30,000 shares of the business’s stock in a transaction that occurred on Friday, February 3rd. The shares were sold at an average price of $258.19, for a total value of $7,745,700.00. Following the completion of the transaction, the chief financial officer now directly owns 81,632 shares in the company, valued at approximately $21,076,566.08. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other HCA Healthcare news, SVP Christopher F. Wyatt sold 4,900 shares of the business’s stock in a transaction on Wednesday, February 1st. The shares were sold at an average price of $253.30, for a total transaction of $1,241,170.00. Following the completion of the sale, the senior vice president now directly owns 32,392 shares in the company, valued at approximately $8,204,893.60. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Bill B. Rutherford sold 30,000 shares of the business’s stock in a transaction on Friday, February 3rd. The shares were sold at an average price of $258.19, for a total transaction of $7,745,700.00. Following the sale, the chief financial officer now owns 81,632 shares of the company’s stock, valued at $21,076,566.08. The disclosure for this sale can be found here. Insiders sold a total of 88,159 shares of company stock worth $22,688,959 in the last three months. Insiders own 1.60% of the company’s stock.

    HCA Healthcare Profile

    (Get Rating)

    HCA Healthcare, Inc is a health care services company engaged in operating hospitals, freestanding surgery centers and emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, radiation and oncology therapy centers, comprehensive rehabilitation and physical therapy centers, physician practices, home health, hospice, outpatient physical therapy home and community-based services providers, and various other facilities.

    Recommended Stories

    Institutional Ownership by Quarter for HCA Healthcare (NYSE:HCA)

    Receive News & Ratings for HCA Healthcare Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for HCA Healthcare and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Janney Montgomery Scott LLC Decreases Stake in Nutrien Ltd. (NYSE:NTR)

    Janney Montgomery Scott LLC Decreases Stake in Nutrien Ltd. (NYSE:NTR)

    [ad_1]

    Janney Montgomery Scott LLC lowered its holdings in Nutrien Ltd. (NYSE:NTR – Get Rating) by 21.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 82,941 shares of the company’s stock after selling 22,676 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Nutrien were worth $6,057,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

    Several other hedge funds have also recently modified their holdings of NTR. BlackRock Inc. raised its stake in shares of Nutrien by 79.6% in the first quarter. BlackRock Inc. now owns 3,490,036 shares of the company’s stock worth $362,929,000 after purchasing an additional 1,547,030 shares during the last quarter. Vontobel Holding Ltd. bought a new stake in shares of Nutrien in the first quarter worth $1,370,000. Sequoia Financial Advisors LLC bought a new stake in shares of Nutrien in the first quarter worth $323,000. Candriam Luxembourg S.C.A. grew its holdings in shares of Nutrien by 5.7% in the first quarter. Candriam Luxembourg S.C.A. now owns 11,675 shares of the company’s stock worth $1,208,000 after acquiring an additional 629 shares during the period. Finally, Zions Bancorporation N.A. grew its holdings in shares of Nutrien by 55.2% in the first quarter. Zions Bancorporation N.A. now owns 301 shares of the company’s stock worth $31,000 after acquiring an additional 107 shares during the period. Hedge funds and other institutional investors own 64.52% of the company’s stock.

    Analyst Upgrades and Downgrades

    Several research firms have issued reports on NTR. Morgan Stanley cut their price target on Nutrien from $91.00 to $80.00 and set an “equal weight” rating for the company in a report on Wednesday, April 12th. HSBC lowered their price objective on Nutrien from $83.00 to $81.00 and set a “hold” rating on the stock in a research report on Tuesday, February 21st. UBS Group lowered their price objective on Nutrien from $100.00 to $99.00 and set a “buy” rating on the stock in a research report on Thursday, April 6th. Royal Bank of Canada lowered their price objective on Nutrien from $115.00 to $110.00 and set an “outperform” rating on the stock in a research report on Tuesday, February 21st. Finally, Barclays lowered their price objective on Nutrien from $95.00 to $93.00 and set an “overweight” rating on the stock in a research report on Friday, April 14th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, Nutrien presently has a consensus rating of “Hold” and a consensus price target of $91.06.

    Nutrien Trading Down 1.4 %

    Shares of NTR stock opened at $72.10 on Friday. Nutrien Ltd. has a 1 year low of $67.52 and a 1 year high of $114.13. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.14 and a quick ratio of 0.61. The stock’s 50 day simple moving average is $75.11 and its two-hundred day simple moving average is $77.43. The company has a market cap of $36.02 billion, a PE ratio of 5.12, a price-to-earnings-growth ratio of 1.07 and a beta of 0.88.

    Nutrien (NYSE:NTR – Get Rating) last released its earnings results on Wednesday, February 15th. The company reported $2.02 EPS for the quarter, missing analysts’ consensus estimates of $2.63 by ($0.61). The business had revenue of $7.53 billion for the quarter, compared to the consensus estimate of $7.41 billion. Nutrien had a net margin of 20.22% and a return on equity of 27.65%. The company’s quarterly revenue was up 3.7% compared to the same quarter last year. During the same period in the prior year, the company posted $2.47 EPS. Research analysts predict that Nutrien Ltd. will post 8.66 earnings per share for the current year.

    Nutrien Increases Dividend

    The firm also recently announced a quarterly dividend, which was paid on Thursday, April 13th. Stockholders of record on Friday, March 31st were paid a dividend of $0.53 per share. This is a boost from Nutrien’s previous quarterly dividend of $0.48. The ex-dividend date was Thursday, March 30th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.94%. Nutrien’s dividend payout ratio is currently 15.05%.

    Nutrien Company Profile

    (Get Rating)

    Nutrien Ltd. is a crop nutrient company, which engages in the production and distribution of products for agricultural, industrial, and feed customer. It operates through the following segments: Retail, Potash, Nitrogen, and Phosphate. The Retail segment distributes crop nutrients, crop protection products, seed, and merchandise.

    See Also

    Institutional Ownership by Quarter for Nutrien (NYSE:NTR)

    Receive News & Ratings for Nutrien Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Nutrien and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Meritage Portfolio Management Decreases Stake in Altria Group, Inc. (NYSE:MO)

    Meritage Portfolio Management Decreases Stake in Altria Group, Inc. (NYSE:MO)

    [ad_1]

    Meritage Portfolio Management cut its holdings in shares of Altria Group, Inc. (NYSE:MO – Get Rating) by 82.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 10,858 shares of the company’s stock after selling 51,867 shares during the quarter. Meritage Portfolio Management’s holdings in Altria Group were worth $496,000 as of its most recent filing with the Securities & Exchange Commission.

    A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Bourgeon Capital Management LLC grew its stake in Altria Group by 85.6% in the 4th quarter. Bourgeon Capital Management LLC now owns 542 shares of the company’s stock valued at $25,000 after buying an additional 250 shares in the last quarter. Loomis Sayles & Co. L P purchased a new position in shares of Altria Group in the first quarter valued at $25,000. Winch Advisory Services LLC raised its stake in shares of Altria Group by 118.8% during the 4th quarter. Winch Advisory Services LLC now owns 805 shares of the company’s stock valued at $37,000 after purchasing an additional 437 shares during the period. MV Capital Management Inc. lifted its holdings in Altria Group by 39.1% during the 4th quarter. MV Capital Management Inc. now owns 886 shares of the company’s stock worth $40,000 after purchasing an additional 249 shares in the last quarter. Finally, 1832 Asset Management L.P. bought a new position in Altria Group in the 1st quarter worth about $41,000. Institutional investors own 58.68% of the company’s stock.

    Analysts Set New Price Targets

    A number of brokerages have recently issued reports on MO. Stifel Nicolaus initiated coverage on shares of Altria Group in a report on Thursday, April 13th. They issued a “buy” rating and a $52.00 price target on the stock. Citigroup decreased their target price on Altria Group from $49.50 to $47.00 and set a “neutral” rating on the stock in a research note on Monday. StockNews.com began coverage on Altria Group in a research report on Thursday, March 16th. They set a “buy” rating for the company. Finally, Morgan Stanley upped their price objective on shares of Altria Group from $43.00 to $46.00 and gave the stock an “equal weight” rating in a research report on Monday, January 23rd. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $45.50.

    Altria Group Price Performance

    Shares of NYSE MO opened at $46.14 on Wednesday. The stock has a market capitalization of $82.41 billion, a P/E ratio of 14.46, a PEG ratio of 2.23 and a beta of 0.59. Altria Group, Inc. has a one year low of $40.35 and a one year high of $57.05. The firm’s 50 day simple moving average is $46.00 and its two-hundred day simple moving average is $45.55.

    Altria Group (NYSE:MO – Get Rating) last announced its quarterly earnings data on Wednesday, February 1st. The company reported $1.18 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.18. Altria Group had a negative return on equity of 284.29% and a net margin of 22.97%. The firm had revenue of $5.08 billion for the quarter, compared to analysts’ expectations of $5.15 billion. During the same period last year, the firm earned $1.09 earnings per share. The company’s revenue for the quarter was down 18.7% compared to the same quarter last year. As a group, equities analysts expect that Altria Group, Inc. will post 5.06 earnings per share for the current fiscal year.

    Altria Group Announces Dividend

    The company also recently announced a quarterly dividend, which will be paid on Friday, April 28th. Stockholders of record on Friday, March 24th will be issued a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 8.15%. The ex-dividend date is Thursday, March 23rd. Altria Group’s dividend payout ratio is 117.87%.

    Altria Group Profile

    (Get Rating)

    Altria Group, Inc operates as a holding company, which engages in the manufacture and sale of cigarettes in the United States. It operates through the following segments: Smokeable Products, Oral tobacco products, and Wine. The Smokeable Products segment consists of cigarettes manufactured and sold by PM USA and machine-made large cigars and pipe tobacco manufactured and sold by Middleton.

    See Also

    Want to see what other hedge funds are holding MO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Altria Group, Inc. (NYSE:MO – Get Rating).

    Institutional Ownership by Quarter for Altria Group (NYSE:MO)

    Receive News & Ratings for Altria Group Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Altria Group and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Kestra Advisory Services LLC Decreases Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

    Kestra Advisory Services LLC Decreases Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

    [ad_1]

    Kestra Advisory Services LLC lowered its stake in shares of Amgen Inc. (NASDAQ:AMGN – Get Rating) by 14.8% during the fourth quarter, Holdings Channel reports. The institutional investor owned 55,910 shares of the medical research company’s stock after selling 9,718 shares during the period. Kestra Advisory Services LLC’s holdings in Amgen were worth $14,684,000 at the end of the most recent reporting period.

    A number of other institutional investors have also recently added to or reduced their stakes in AMGN. EdgeRock Capital LLC acquired a new position in Amgen during the third quarter worth about $25,000. Leelyn Smith LLC raised its position in Amgen by 80.3% during the third quarter. Leelyn Smith LLC now owns 110 shares of the medical research company’s stock worth $25,000 after acquiring an additional 49 shares during the last quarter. Glassy Mountain Advisors Inc. acquired a new position in Amgen during the fourth quarter worth about $26,000. Legacy Bridge LLC raised its position in Amgen by 930.0% during the fourth quarter. Legacy Bridge LLC now owns 103 shares of the medical research company’s stock worth $27,000 after acquiring an additional 93 shares during the last quarter. Finally, RFP Financial Group LLC acquired a new position in Amgen during the fourth quarter worth about $33,000. Hedge funds and other institutional investors own 75.53% of the company’s stock.

    Amgen Price Performance

    AMGN opened at $250.00 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.41 and a debt-to-equity ratio of 10.20. Amgen Inc. has a 52-week low of $223.30 and a 52-week high of $296.67. The company has a 50 day moving average of $239.01 and a two-hundred day moving average of $255.87. The company has a market cap of $133.56 billion, a P/E ratio of 20.64, a P/E/G ratio of 2.03 and a beta of 0.64.

    Amgen (NASDAQ:AMGN – Get Rating) last released its quarterly earnings data on Tuesday, February 7th. The medical research company reported $4.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.04 by $0.05. Amgen had a net margin of 24.89% and a return on equity of 359.47%. The company had revenue of $6.84 billion during the quarter, compared to the consensus estimate of $6.77 billion. During the same period in the previous year, the firm earned $4.36 earnings per share. Amgen’s revenue for the quarter was down .1% on a year-over-year basis. On average, analysts expect that Amgen Inc. will post 17.73 earnings per share for the current year.

    Amgen Announces Dividend

    The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 8th. Shareholders of record on Thursday, May 18th will be paid a dividend of $2.13 per share. The ex-dividend date of this dividend is Wednesday, May 17th. This represents a $8.52 annualized dividend and a yield of 3.41%. Amgen’s dividend payout ratio is currently 70.36%.

    Wall Street Analysts Forecast Growth

    AMGN has been the subject of a number of research reports. SVB Securities cut their target price on shares of Amgen from $282.00 to $267.00 in a research report on Thursday, February 2nd. Truist Financial cut their price objective on shares of Amgen from $280.00 to $260.00 and set a “buy” rating for the company in a research report on Monday, February 13th. Argus cut their price objective on shares of Amgen from $300.00 to $270.00 in a research report on Monday, February 6th. Wells Fargo & Company raised shares of Amgen from an “equal weight” rating to an “overweight” rating and cut their price objective for the company from $275.00 to $265.00 in a research report on Monday, March 13th. Finally, Cowen cut their price objective on shares of Amgen from $307.00 to $289.00 and set an “outperform” rating for the company in a research report on Wednesday, February 1st. Four equities research analysts have rated the stock with a sell rating, three have given a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $251.25.

    Amgen Profile

    (Get Rating)

    Amgen, Inc is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

    Featured Stories

    Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Get Rating).

    Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

    Receive News & Ratings for Amgen Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Amgen and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Geneos Wealth Management Inc. Grows Stock Position in Palantir Technologies Inc. (NYSE:PLTR)

    Geneos Wealth Management Inc. Grows Stock Position in Palantir Technologies Inc. (NYSE:PLTR)

    [ad_1]

    Geneos Wealth Management Inc. lifted its holdings in shares of Palantir Technologies Inc. (NYSE:PLTR – Get Rating) by 2.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 108,891 shares of the company’s stock after purchasing an additional 2,200 shares during the period. Geneos Wealth Management Inc.’s holdings in Palantir Technologies were worth $699,000 as of its most recent SEC filing.

    Several other hedge funds also recently bought and sold shares of PLTR. QCM Cayman Ltd. acquired a new stake in Palantir Technologies in the 4th quarter worth about $111,000. New York State Common Retirement Fund increased its stake in Palantir Technologies by 2.0% during the 4th quarter. New York State Common Retirement Fund now owns 1,939,758 shares of the company’s stock worth $12,453,000 after buying an additional 37,700 shares during the period. Kistler Tiffany Companies LLC acquired a new position in Palantir Technologies in the 4th quarter worth $48,000. International Assets Investment Management LLC grew its stake in shares of Palantir Technologies by 93.6% during the fourth quarter. International Assets Investment Management LLC now owns 147,688 shares of the company’s stock valued at $948,000 after acquiring an additional 71,402 shares in the last quarter. Finally, Barnes Pettey Financial Advisors LLC purchased a new stake in shares of Palantir Technologies during the fourth quarter worth about $1,471,000. Hedge funds and other institutional investors own 31.90% of the company’s stock.

    Palantir Technologies Stock Performance

    Shares of NYSE:PLTR opened at $8.58 on Friday. Palantir Technologies Inc. has a 1-year low of $5.84 and a 1-year high of $13.33. The company has a 50 day moving average price of $8.27 and a 200 day moving average price of $7.72.

    Palantir Technologies (NYSE:PLTR – Get Rating) last issued its earnings results on Monday, February 13th. The company reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.03 by $0.01. Palantir Technologies had a negative return on equity of 11.90% and a negative net margin of 19.61%. The business had revenue of $508.62 million for the quarter, compared to analysts’ expectations of $504.84 million. During the same period in the previous year, the firm posted $0.02 EPS. The company’s quarterly revenue was up 17.5% on a year-over-year basis. Sell-side analysts predict that Palantir Technologies Inc. will post 0.05 earnings per share for the current year.

    Analyst Upgrades and Downgrades

    A number of brokerages have issued reports on PLTR. Deutsche Bank Aktiengesellschaft cut their target price on Palantir Technologies from $7.00 to $6.00 and set a “sell” rating on the stock in a research report on Monday, January 23rd. Morgan Stanley dropped their target price on shares of Palantir Technologies from $10.00 to $8.00 and set an “equal weight” rating for the company in a research report on Monday, December 19th. Mizuho increased their price target on shares of Palantir Technologies from $7.00 to $8.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 14th. The Goldman Sachs Group lowered their price objective on Palantir Technologies from $9.00 to $8.00 and set a “neutral” rating for the company in a report on Tuesday, February 14th. Finally, DA Davidson assumed coverage on Palantir Technologies in a report on Tuesday, February 28th. They set a “neutral” rating and a $8.00 target price on the stock. Five equities research analysts have rated the stock with a sell rating, seven have issued a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $8.85.

    Insiders Place Their Bets

    In other Palantir Technologies news, insider Ryan D. Taylor sold 153,049 shares of the firm’s stock in a transaction dated Wednesday, February 15th. The shares were sold at an average price of $10.07, for a total value of $1,541,203.43. Following the completion of the transaction, the insider now directly owns 281,526 shares in the company, valued at $2,834,966.82. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other Palantir Technologies news, insider Jeffrey Buckley sold 4,636 shares of the company’s stock in a transaction dated Tuesday, February 21st. The stock was sold at an average price of $8.55, for a total value of $39,637.80. Following the transaction, the insider now directly owns 334,051 shares of the company’s stock, valued at approximately $2,856,136.05. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Ryan D. Taylor sold 153,049 shares of the firm’s stock in a transaction dated Wednesday, February 15th. The stock was sold at an average price of $10.07, for a total value of $1,541,203.43. Following the sale, the insider now directly owns 281,526 shares of the company’s stock, valued at $2,834,966.82. The disclosure for this sale can be found here. In the last quarter, insiders have sold 206,462 shares of company stock worth $1,980,256. Company insiders own 13.71% of the company’s stock.

    About Palantir Technologies

    (Get Rating)

    Palantir Technologies Inc builds and deploys software platforms for the intelligence community in the United States to assist in counterterrorism investigations and operations. The company provides palantir gotham, a software platform which enables users to identify patterns hidden deep within datasets, ranging from signals intelligence sources to reports from confidential informants, as well as facilitates the handoff between analysts and operational users, helping operators plan and execute real-world responses to threats that have been identified within the platform.

    See Also

    Institutional Ownership by Quarter for Palantir Technologies (NYSE:PLTR)

    Receive News & Ratings for Palantir Technologies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Palantir Technologies and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Bernardo Wealth Planning LLC Reduces Stake in Abbott Laboratories (NYSE:ABT)

    Bernardo Wealth Planning LLC Reduces Stake in Abbott Laboratories (NYSE:ABT)

    [ad_1]

    Bernardo Wealth Planning LLC trimmed its stake in Abbott Laboratories (NYSE:ABT – Get Rating) by 8.2% during the fourth quarter, Holdings Channel reports. The fund owned 2,400 shares of the healthcare product maker’s stock after selling 213 shares during the period. Bernardo Wealth Planning LLC’s holdings in Abbott Laboratories were worth $264,000 as of its most recent filing with the Securities & Exchange Commission.

    Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. JDM Financial Group LLC purchased a new stake in shares of Abbott Laboratories during the 4th quarter valued at approximately $26,000. EdgeRock Capital LLC purchased a new stake in shares of Abbott Laboratories during the 3rd quarter valued at approximately $29,000. Johnson Midwest Financial LLC lifted its stake in shares of Abbott Laboratories by 28.7% during the 3rd quarter. Johnson Midwest Financial LLC now owns 560 shares of the healthcare product maker’s stock valued at $35,000 after buying an additional 125 shares in the last quarter. Arcus Capital Partners LLC purchased a new stake in shares of Abbott Laboratories during the 4th quarter valued at approximately $35,000. Finally, Glassy Mountain Advisors Inc. purchased a new stake in shares of Abbott Laboratories during the 4th quarter valued at approximately $44,000. 72.93% of the stock is currently owned by hedge funds and other institutional investors.

    Insiders Place Their Bets

    In other news, EVP Andrea F. Wainer sold 679 shares of the firm’s stock in a transaction dated Wednesday, March 1st. The shares were sold at an average price of $100.70, for a total value of $68,375.30. Following the completion of the sale, the executive vice president now directly owns 70,427 shares of the company’s stock, valued at approximately $7,091,998.90. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, SVP Randel William Woodgrift sold 1,032 shares of the firm’s stock in a transaction dated Wednesday, March 1st. The shares were sold at an average price of $100.70, for a total value of $103,922.40. Following the completion of the sale, the senior vice president now directly owns 52,203 shares of the company’s stock, valued at approximately $5,256,842.10. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Andrea F. Wainer sold 679 shares of the firm’s stock in a transaction dated Wednesday, March 1st. The stock was sold at an average price of $100.70, for a total transaction of $68,375.30. Following the completion of the sale, the executive vice president now directly owns 70,427 shares of the company’s stock, valued at $7,091,998.90. The disclosure for this sale can be found here. Insiders have sold a total of 1,971 shares of company stock valued at $199,140 in the last quarter. Insiders own 1.10% of the company’s stock.

    Analyst Ratings Changes

    A number of brokerages recently commented on ABT. Wells Fargo & Company dropped their price target on shares of Abbott Laboratories from $140.00 to $136.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 5th. Sanford C. Bernstein increased their target price on shares of Abbott Laboratories from $125.00 to $132.00 and gave the stock an “outperform” rating in a research note on Thursday, January 26th. StockNews.com assumed coverage on shares of Abbott Laboratories in a research note on Thursday, March 16th. They issued a “buy” rating on the stock. SVB Leerink increased their target price on shares of Abbott Laboratories from $90.00 to $102.00 and gave the stock a “market perform” rating in a research note on Friday, March 31st. Finally, Barclays increased their target price on shares of Abbott Laboratories from $122.00 to $125.00 and gave the stock an “overweight” rating in a research note on Friday, January 27th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $121.88.

    Abbott Laboratories Price Performance

    ABT stock opened at $103.70 on Tuesday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.23 and a current ratio of 1.63. Abbott Laboratories has a 52 week low of $93.25 and a 52 week high of $124.35. The firm’s fifty day moving average is $102.99 and its 200 day moving average is $104.43. The firm has a market cap of $180.23 billion, a P/E ratio of 26.52, a P/E/G ratio of 4.71 and a beta of 0.67.

    Abbott Laboratories (NYSE:ABT – Get Rating) last released its earnings results on Wednesday, January 25th. The healthcare product maker reported $1.03 EPS for the quarter, beating the consensus estimate of $0.90 by $0.13. The company had revenue of $10.09 billion for the quarter, compared to analyst estimates of $9.69 billion. Abbott Laboratories had a net margin of 15.88% and a return on equity of 26.09%. The firm’s quarterly revenue was down 12.0% compared to the same quarter last year. During the same quarter last year, the firm earned $1.32 EPS. Research analysts predict that Abbott Laboratories will post 4.38 earnings per share for the current year.

    Abbott Laboratories Announces Dividend

    The company also recently declared a quarterly dividend, which will be paid on Monday, May 15th. Shareholders of record on Friday, April 14th will be issued a $0.51 dividend. This represents a $2.04 dividend on an annualized basis and a yield of 1.97%. The ex-dividend date of this dividend is Thursday, April 13th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 52.17%.

    Abbott Laboratories Company Profile

    (Get Rating)

    Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products.

    Featured Articles

    Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Get Rating).

    Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

    Receive News & Ratings for Abbott Laboratories Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Abbott Laboratories and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • 7,575 Shares in iShares U.S. Technology ETF (NYSEARCA:IYW) Purchased by Baker Tilly Wealth Management LLC

    7,575 Shares in iShares U.S. Technology ETF (NYSEARCA:IYW) Purchased by Baker Tilly Wealth Management LLC

    [ad_1]

    Baker Tilly Wealth Management LLC acquired a new stake in iShares U.S. Technology ETF (NYSEARCA:IYW – Get Rating) in the 4th quarter, according to the company in its most recent filing with the SEC. The firm acquired 7,575 shares of the exchange traded fund’s stock, valued at approximately $564,000.

    Other hedge funds and other institutional investors have also bought and sold shares of the company. BlackRock Inc. grew its position in iShares U.S. Technology ETF by 3,385.0% during the first quarter. BlackRock Inc. now owns 22,513 shares of the exchange traded fund’s stock valued at $2,320,000 after acquiring an additional 21,867 shares during the last quarter. Blair William & Co. IL raised its stake in iShares U.S. Technology ETF by 3.7% during the first quarter. Blair William & Co. IL now owns 27,457 shares of the exchange traded fund’s stock valued at $2,829,000 after buying an additional 990 shares during the last quarter. Sequoia Financial Advisors LLC grew its holdings in shares of iShares U.S. Technology ETF by 4.6% during the first quarter. Sequoia Financial Advisors LLC now owns 5,659 shares of the exchange traded fund’s stock valued at $583,000 after buying an additional 247 shares during the last quarter. First Western Trust Bank bought a new stake in shares of iShares U.S. Technology ETF in the 1st quarter worth $702,000. Finally, Equitable Holdings Inc. raised its position in iShares U.S. Technology ETF by 3.3% in the 1st quarter. Equitable Holdings Inc. now owns 8,207 shares of the exchange traded fund’s stock worth $846,000 after buying an additional 266 shares during the last quarter.

    iShares U.S. Technology ETF Stock Performance

    iShares U.S. Technology ETF stock opened at $92.01 on Friday. The stock has a market cap of $9.75 billion, a PE ratio of 21.40 and a beta of 1.12. The stock has a fifty day moving average of $86.89 and a 200 day moving average of $80.30. iShares U.S. Technology ETF has a one year low of $69.49 and a one year high of $100.59.

    About iShares U.S. Technology ETF

    (Get Rating)

    iShares U.S. Technology ETF, formerly iShares Dow Jones U.S. Technology Sector Index Fund (the Fund) is a non-diversified fund. The Fund seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of the Dow Jones U.S. Technology Index (the Index).

    Further Reading

    Institutional Ownership by Quarter for iShares U.S. Technology ETF (NYSEARCA:IYW)

    Receive News & Ratings for iShares U.S. Technology ETF Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for iShares U.S. Technology ETF and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Eli Lilly and Company (NYSE:LLY) Position Decreased by Strategic Blueprint LLC

    Eli Lilly and Company (NYSE:LLY) Position Decreased by Strategic Blueprint LLC

    [ad_1]

    Strategic Blueprint LLC reduced its holdings in Eli Lilly and Company (NYSE:LLY – Get Rating) by 8.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,703 shares of the company’s stock after selling 423 shares during the quarter. Strategic Blueprint LLC’s holdings in Eli Lilly and were worth $1,720,000 at the end of the most recent quarter.

    Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Benjamin Edwards Inc. boosted its position in Eli Lilly and by 0.7% during the third quarter. Benjamin Edwards Inc. now owns 3,836 shares of the company’s stock worth $1,240,000 after purchasing an additional 28 shares during the period. Moloney Securities Asset Management LLC boosted its holdings in shares of Eli Lilly and by 0.6% during the 3rd quarter. Moloney Securities Asset Management LLC now owns 5,000 shares of the company’s stock worth $1,617,000 after buying an additional 28 shares during the period. Auxano Advisors LLC grew its stake in Eli Lilly and by 2.1% in the 3rd quarter. Auxano Advisors LLC now owns 1,385 shares of the company’s stock valued at $448,000 after buying an additional 28 shares during the last quarter. Hexagon Capital Partners LLC raised its holdings in Eli Lilly and by 4.6% in the 4th quarter. Hexagon Capital Partners LLC now owns 633 shares of the company’s stock valued at $232,000 after acquiring an additional 28 shares during the period. Finally, Wedge Capital Management L L P NC lifted its position in Eli Lilly and by 1.9% during the fourth quarter. Wedge Capital Management L L P NC now owns 1,485 shares of the company’s stock worth $543,000 after acquiring an additional 28 shares during the last quarter. 82.13% of the stock is owned by institutional investors and hedge funds.

    Eli Lilly and Stock Up 1.7 %

    LLY stock opened at $368.29 on Friday. The stock’s 50 day moving average is $332.95 and its 200-day moving average is $344.45. Eli Lilly and Company has a twelve month low of $276.83 and a twelve month high of $384.44. The firm has a market capitalization of $349.99 billion, a PE ratio of 53.38, a P/E/G ratio of 2.01 and a beta of 0.36. The company has a quick ratio of 0.80, a current ratio of 1.05 and a debt-to-equity ratio of 1.37.

    Eli Lilly and (NYSE:LLY – Get Rating) last issued its quarterly earnings data on Thursday, February 2nd. The company reported $2.09 earnings per share for the quarter, beating the consensus estimate of $1.83 by $0.26. The business had revenue of $7.30 billion for the quarter, compared to analysts’ expectations of $7.39 billion. Eli Lilly and had a return on equity of 73.61% and a net margin of 21.88%. The business’s revenue was down 8.7% on a year-over-year basis. During the same period last year, the business earned $2.49 EPS. Sell-side analysts expect that Eli Lilly and Company will post 8.49 EPS for the current fiscal year.

    Insider Buying and Selling at Eli Lilly and

    In other news, major shareholder Lilly Endowment Inc sold 210,000 shares of the business’s stock in a transaction that occurred on Monday, April 3rd. The stock was sold at an average price of $350.49, for a total value of $73,602,900.00. Following the transaction, the insider now owns 102,333,810 shares in the company, valued at approximately $35,866,977,066.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, major shareholder Lilly Endowment Inc sold 210,000 shares of the business’s stock in a transaction dated Monday, April 3rd. The shares were sold at an average price of $350.49, for a total value of $73,602,900.00. Following the transaction, the insider now directly owns 102,333,810 shares of the company’s stock, valued at approximately $35,866,977,066.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Anne E. White sold 2,500 shares of the firm’s stock in a transaction dated Friday, February 10th. The stock was sold at an average price of $342.76, for a total transaction of $856,900.00. Following the sale, the executive vice president now owns 60,426 shares of the company’s stock, valued at approximately $20,711,615.76. The disclosure for this sale can be found here. In the last 90 days, insiders sold 689,703 shares of company stock worth $237,930,004. Insiders own 0.13% of the company’s stock.

    Wall Street Analysts Forecast Growth

    Several analysts recently issued reports on the company. StockNews.com began coverage on Eli Lilly and in a research note on Thursday, March 16th. They issued a “buy” rating for the company. Societe Generale cut shares of Eli Lilly and from a “hold” rating to a “sell” rating and set a $278.00 price target on the stock. in a research report on Wednesday, February 15th. Citigroup lowered their price objective on Eli Lilly and from $370.00 to $360.00 and set a “buy” rating for the company in a research report on Friday, March 3rd. Wells Fargo & Company upgraded Eli Lilly and from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $360.00 to $375.00 in a research report on Monday, March 13th. Finally, JPMorgan Chase & Co. lifted their target price on Eli Lilly and from $380.00 to $400.00 in a report on Wednesday, December 14th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $383.11.

    Eli Lilly and Company Profile

    (Get Rating)

    Eli Lilly & Co engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm’s products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

    See Also

    Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Get Rating).

    Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

    Receive News & Ratings for Eli Lilly and Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Eli Lilly and and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Whittier Trust Co. Cuts Stock Position in PayPal Holdings, Inc. (NASDAQ:PYPL)

    Whittier Trust Co. Cuts Stock Position in PayPal Holdings, Inc. (NASDAQ:PYPL)

    [ad_1]

    Whittier Trust Co. trimmed its position in PayPal Holdings, Inc. (NASDAQ:PYPL – Get Rating) by 24.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,795 shares of the credit services provider’s stock after selling 6,239 shares during the period. Whittier Trust Co.’s holdings in PayPal were worth $1,410,000 as of its most recent SEC filing.

    Several other institutional investors also recently bought and sold shares of PYPL. Joseph Group Capital Management purchased a new stake in shares of PayPal in the third quarter valued at about $26,000. Arlington Partners LLC acquired a new position in PayPal during the 4th quarter worth approximately $27,000. RFP Financial Group LLC purchased a new position in shares of PayPal during the 4th quarter worth approximately $27,000. Old North State Trust LLC acquired a new stake in shares of PayPal in the 3rd quarter valued at approximately $29,000. Finally, New Millennium Group LLC purchased a new stake in shares of PayPal in the second quarter valued at approximately $30,000. 72.12% of the stock is owned by institutional investors and hedge funds.

    Analysts Set New Price Targets

    Several research firms have issued reports on PYPL. Wells Fargo & Company increased their price objective on PayPal from $95.00 to $97.00 and gave the stock an “overweight” rating in a research report on Friday, February 10th. UBS Group boosted their price objective on shares of PayPal to $125.00 in a report on Monday, December 12th. BNP Paribas raised shares of PayPal from a “neutral” rating to an “outperform” rating in a report on Tuesday, January 3rd. Raymond James downgraded shares of PayPal from an “outperform” rating to a “market perform” rating in a research report on Monday, February 6th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $160.00 price objective on shares of PayPal in a research note on Friday, February 10th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and twenty-four have assigned a buy rating to the stock. According to MarketBeat.com, PayPal has an average rating of “Moderate Buy” and a consensus target price of $108.42.

    PayPal Price Performance

    PayPal stock opened at $73.61 on Thursday. PayPal Holdings, Inc. has a 1 year low of $66.39 and a 1 year high of $115.52. The firm has a 50 day moving average price of $76.49 and a 200 day moving average price of $79.06. The company has a market cap of $83.28 billion, a price-to-earnings ratio of 35.05, a PEG ratio of 1.13 and a beta of 1.31. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.28 and a current ratio of 1.28.

    PayPal (NASDAQ:PYPL – Get Rating) last released its earnings results on Thursday, February 9th. The credit services provider reported $1.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.20 by $0.04. PayPal had a net margin of 8.79% and a return on equity of 17.48%. The firm had revenue of $7.38 billion during the quarter, compared to the consensus estimate of $7.39 billion. During the same period in the previous year, the firm earned $0.92 earnings per share. PayPal’s revenue was up 6.7% compared to the same quarter last year. Sell-side analysts predict that PayPal Holdings, Inc. will post 3.83 earnings per share for the current year.

    Insider Buying and Selling at PayPal

    In other PayPal news, CEO Daniel H. Schulman purchased 26,065 shares of PayPal stock in a transaction on Friday, February 17th. The shares were purchased at an average cost of $76.17 per share, with a total value of $1,985,371.05. Following the completion of the transaction, the chief executive officer now directly owns 395,351 shares in the company, valued at approximately $30,113,885.67. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.13% of the stock is currently owned by corporate insiders.

    About PayPal

    (Get Rating)

    PayPal Holdings, Inc engages in the development of technology platforms for digital payments. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. It manages a two-sided proprietary global technology platform that links customers, which consist of both merchants and consumers, to facilitate the processing of payment transactions.

    Recommended Stories

    Want to see what other hedge funds are holding PYPL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PayPal Holdings, Inc. (NASDAQ:PYPL – Get Rating).

    Institutional Ownership by Quarter for PayPal (NASDAQ:PYPL)

    Receive News & Ratings for PayPal Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for PayPal and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Diversified Portfolios Inc. Lowers Stake in Comcast Co. (NASDAQ:CMCSA)

    Diversified Portfolios Inc. Lowers Stake in Comcast Co. (NASDAQ:CMCSA)

    [ad_1]

    Diversified Portfolios Inc. trimmed its holdings in shares of Comcast Co. (NASDAQ:CMCSA – Get Rating) by 37.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,017 shares of the cable giant’s stock after selling 2,963 shares during the period. Diversified Portfolios Inc.’s holdings in Comcast were worth $175,000 at the end of the most recent reporting period.

    A number of other hedge funds and other institutional investors have also recently bought and sold shares of CMCSA. Kolinsky Wealth Management LLC grew its position in Comcast by 2.2% during the 2nd quarter. Kolinsky Wealth Management LLC now owns 13,749 shares of the cable giant’s stock worth $540,000 after purchasing an additional 291 shares during the period. McLean Asset Management Corp grew its position in shares of Comcast by 2.6% during the 4th quarter. McLean Asset Management Corp now owns 11,389 shares of the cable giant’s stock valued at $398,000 after acquiring an additional 293 shares during the period. Kovack Advisors Inc. grew its position in shares of Comcast by 1.2% during the 3rd quarter. Kovack Advisors Inc. now owns 25,912 shares of the cable giant’s stock valued at $760,000 after acquiring an additional 308 shares during the period. Signet Investment Advisory Group Inc. grew its position in shares of Comcast by 1.2% during the 4th quarter. Signet Investment Advisory Group Inc. now owns 26,331 shares of the cable giant’s stock valued at $921,000 after acquiring an additional 316 shares during the period. Finally, Beach Investment Counsel Inc. PA grew its position in shares of Comcast by 2.5% during the 3rd quarter. Beach Investment Counsel Inc. PA now owns 13,036 shares of the cable giant’s stock valued at $382,000 after acquiring an additional 319 shares during the period. 82.23% of the stock is owned by institutional investors and hedge funds.

    Comcast Stock Performance

    Shares of CMCSA opened at $37.91 on Friday. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.78 and a current ratio of 0.78. The company has a market capitalization of $159.83 billion, a price-to-earnings ratio of 31.86, a PEG ratio of 0.81 and a beta of 1.00. The company’s 50 day simple moving average is $37.81 and its 200 day simple moving average is $35.19. Comcast Co. has a 1 year low of $28.39 and a 1 year high of $48.42.

    Comcast (NASDAQ:CMCSA – Get Rating) last posted its quarterly earnings results on Thursday, January 26th. The cable giant reported $0.82 earnings per share for the quarter, topping analysts’ consensus estimates of $0.78 by $0.04. The company had revenue of $30.55 billion for the quarter, compared to the consensus estimate of $30.36 billion. Comcast had a net margin of 4.42% and a return on equity of 18.40%. Comcast’s revenue was up .7% on a year-over-year basis. During the same quarter last year, the firm posted $0.77 earnings per share. On average, sell-side analysts predict that Comcast Co. will post 3.64 EPS for the current year.

    Comcast Increases Dividend

    The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 26th. Stockholders of record on Wednesday, April 5th will be given a $0.29 dividend. The ex-dividend date of this dividend is Tuesday, April 4th. This represents a $1.16 annualized dividend and a dividend yield of 3.06%. This is a positive change from Comcast’s previous quarterly dividend of $0.27. Comcast’s dividend payout ratio is presently 90.76%.

    Insider Activity at Comcast

    In related news, major shareholder Corp Comcast sold 1,610,496 shares of the firm’s stock in a transaction on Wednesday, February 1st. The shares were sold at an average price of $2.38, for a total transaction of $3,832,980.48. Following the completion of the sale, the insider now directly owns 25,153,615 shares of the company’s stock, valued at approximately $59,865,603.70. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In the last three months, insiders sold 7,527,791 shares of company stock valued at $19,025,007. Corporate insiders own 1.11% of the company’s stock.

    Wall Street Analyst Weigh In

    A number of research firms have recently commented on CMCSA. Barclays raised their target price on Comcast from $34.00 to $36.00 and gave the company an “equal weight” rating in a research report on Thursday, February 2nd. JPMorgan Chase & Co. raised their price target on shares of Comcast from $40.00 to $43.00 and gave the company a “neutral” rating in a research note on Friday, January 27th. Rosenblatt Securities raised their price target on shares of Comcast from $32.00 to $38.00 and gave the company a “neutral” rating in a research note on Friday, January 27th. Pivotal Research raised their target price on shares of Comcast from $42.00 to $47.00 and gave the stock a “buy” rating in a research note on Friday, January 27th. Finally, Cowen decreased their target price on shares of Comcast from $49.00 to $46.00 and set an “outperform” rating on the stock in a research note on Friday, January 27th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $44.29.

    Comcast Profile

    (Get Rating)

    Comcast Corp. engages in the provision of video, Internet, and phone services. It operates through the following segments: Cable Communications, Media, Studios, Theme Parks, and Sky. The Cable Communications segment consists of Comcast Cable, which is a provider of broadband, video, voice, wireless, and other services to residential customers in the United States under the Xfinity brand.

    Read More

    Want to see what other hedge funds are holding CMCSA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Comcast Co. (NASDAQ:CMCSA – Get Rating).

    Institutional Ownership by Quarter for Comcast (NASDAQ:CMCSA)

    Receive News & Ratings for Comcast Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Comcast and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Pfizer Inc. (NYSE:PFE) Shares Sold by Grandfield & Dodd LLC

    Pfizer Inc. (NYSE:PFE) Shares Sold by Grandfield & Dodd LLC

    [ad_1]

    Grandfield & Dodd LLC reduced its stake in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 3.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 79,604 shares of the biopharmaceutical company’s stock after selling 3,090 shares during the period. Grandfield & Dodd LLC’s holdings in Pfizer were worth $4,079,000 at the end of the most recent quarter.

    A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Front Street Capital Management Inc. grew its stake in Pfizer by 4.3% during the 1st quarter. Front Street Capital Management Inc. now owns 5,168 shares of the biopharmaceutical company’s stock valued at $268,000 after acquiring an additional 215 shares in the last quarter. Lindenwold Advisors grew its stake in Pfizer by 1.0% during the 3rd quarter. Lindenwold Advisors now owns 21,151 shares of the biopharmaceutical company’s stock valued at $926,000 after acquiring an additional 216 shares in the last quarter. SRS Capital Advisors Inc. grew its stake in shares of Pfizer by 1.6% in the 2nd quarter. SRS Capital Advisors Inc. now owns 13,618 shares of the biopharmaceutical company’s stock valued at $714,000 after buying an additional 218 shares during the period. Signet Financial Management LLC grew its stake in shares of Pfizer by 0.6% in the 3rd quarter. Signet Financial Management LLC now owns 34,338 shares of the biopharmaceutical company’s stock valued at $1,503,000 after buying an additional 220 shares during the period. Finally, Mitchell Mcleod Pugh & Williams Inc. grew its stake in shares of Pfizer by 0.7% in the 3rd quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 33,978 shares of the biopharmaceutical company’s stock valued at $1,487,000 after buying an additional 222 shares during the period. 67.62% of the stock is currently owned by institutional investors and hedge funds.

    Pfizer Stock Performance

    PFE opened at $40.25 on Thursday. The company has a market capitalization of $227.19 billion, a price-to-earnings ratio of 7.34, a price-to-earnings-growth ratio of 1.35 and a beta of 0.64. The company has a debt-to-equity ratio of 0.34, a current ratio of 1.22 and a quick ratio of 1.00. Pfizer Inc. has a 1-year low of $39.23 and a 1-year high of $56.32. The business has a 50 day moving average price of $42.16 and a two-hundred day moving average price of $45.70.

    Pfizer (NYSE:PFE – Get Rating) last posted its quarterly earnings results on Tuesday, January 31st. The biopharmaceutical company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.03 by $0.11. The company had revenue of $24.30 billion for the quarter, compared to analysts’ expectations of $24.40 billion. Pfizer had a return on equity of 42.03% and a net margin of 31.27%. The firm’s revenue was up 1.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.08 earnings per share. Research analysts predict that Pfizer Inc. will post 3.3 EPS for the current fiscal year.

    Insider Buying and Selling at Pfizer

    In other news, major shareholder Pfizer Inc bought 1,811,594 shares of the business’s stock in a transaction on Friday, March 17th. The shares were bought at an average cost of $2.76 per share, with a total value of $4,999,999.44. Following the purchase, the insider now directly owns 5,952,263 shares in the company, valued at $16,428,245.88. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 0.05% of the company’s stock.

    Wall Street Analysts Forecast Growth

    PFE has been the subject of several analyst reports. Morgan Stanley dropped their price target on shares of Pfizer from $53.00 to $45.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 1st. Jefferies Financial Group started coverage on shares of Pfizer in a report on Monday, March 6th. They issued a “hold” rating and a $43.00 price objective on the stock. Wells Fargo & Company reduced their target price on shares of Pfizer from $50.00 to $44.00 and set an “equal weight” rating on the stock in a report on Friday, March 17th. Atlantic Securities reduced their target price on shares of Pfizer from $50.00 to $46.00 and set a “neutral” rating on the stock in a report on Wednesday, February 1st. Finally, UBS Group set a $45.00 price objective on shares of Pfizer in a research report on Tuesday, March 14th. Nine research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, Pfizer presently has an average rating of “Hold” and a consensus target price of $50.38.

    Pfizer Company Profile

    (Get Rating)

    Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.

    Featured Stories

    Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Get Rating).

    Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

    Receive News & Ratings for Pfizer Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Amgen Inc. (NASDAQ:AMGN) Shares Sold by Plimoth Trust Co. LLC

    Amgen Inc. (NASDAQ:AMGN) Shares Sold by Plimoth Trust Co. LLC

    [ad_1]

    Plimoth Trust Co. LLC lowered its position in Amgen Inc. (NASDAQ:AMGN – Get Rating) by 3.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,251 shares of the medical research company’s stock after selling 165 shares during the quarter. Plimoth Trust Co. LLC’s holdings in Amgen were worth $1,117,000 as of its most recent filing with the Securities and Exchange Commission.

    A number of other hedge funds also recently made changes to their positions in the business. EdgeRock Capital LLC acquired a new stake in shares of Amgen in the third quarter valued at $25,000. Leelyn Smith LLC boosted its position in shares of Amgen by 80.3% in the 3rd quarter. Leelyn Smith LLC now owns 110 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 49 shares during the period. Capital Wealth Alliance LLC purchased a new position in shares of Amgen in the second quarter worth approximately $26,000. Glassy Mountain Advisors Inc. acquired a new stake in Amgen during the 4th quarter valued at $26,000. Finally, Coston McIsaac & Partners purchased a new stake in Amgen in the 2nd quarter worth about $27,000. Institutional investors own 75.53% of the company’s stock.

    Amgen Trading Up 0.7 %

    Shares of Amgen stock opened at $239.64 on Monday. The company has a debt-to-equity ratio of 10.20, a current ratio of 1.41 and a quick ratio of 1.10. The business has a fifty day simple moving average of $242.09 and a two-hundred day simple moving average of $254.57. Amgen Inc. has a 1 year low of $223.30 and a 1 year high of $296.67. The company has a market capitalization of $127.96 billion, a price-to-earnings ratio of 19.66, a P/E/G ratio of 1.92 and a beta of 0.65.

    Amgen (NASDAQ:AMGN – Get Rating) last announced its earnings results on Tuesday, February 7th. The medical research company reported $4.09 EPS for the quarter, topping the consensus estimate of $4.04 by $0.05. The business had revenue of $6.84 billion during the quarter, compared to the consensus estimate of $6.77 billion. Amgen had a net margin of 24.89% and a return on equity of 359.47%. Amgen’s revenue was down .1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $4.36 EPS. Research analysts forecast that Amgen Inc. will post 17.72 EPS for the current year.

    Amgen Dividend Announcement

    The company also recently declared a quarterly dividend, which will be paid on Thursday, June 8th. Investors of record on Thursday, May 18th will be issued a dividend of $2.13 per share. The ex-dividend date of this dividend is Wednesday, May 17th. This represents a $8.52 annualized dividend and a yield of 3.56%. Amgen’s payout ratio is currently 70.36%.

    Wall Street Analyst Weigh In

    A number of research analysts have commented on AMGN shares. Credit Suisse Group lowered their target price on Amgen from $240.00 to $220.00 and set an “underperform” rating on the stock in a research note on Wednesday, February 1st. BMO Capital Markets reduced their price objective on Amgen from $276.00 to $253.00 and set a “market perform” rating for the company in a research report on Wednesday, February 1st. Piper Sandler reduced their price objective on Amgen from $299.00 to $293.00 and set an “overweight” rating for the company in a research report on Thursday, January 19th. SVB Leerink lowered their target price on shares of Amgen from $282.00 to $267.00 and set a “market perform” rating on the stock in a research note on Thursday, February 2nd. Finally, Barclays dropped their price objective on Amgen from $240.00 to $230.00 and set an “underweight” rating for the company in a research note on Wednesday, February 1st. Four equities research analysts have rated the stock with a sell rating, three have assigned a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Amgen has a consensus rating of “Hold” and an average target price of $251.44.

    Amgen Profile

    (Get Rating)

    Amgen, Inc is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

    Read More

    Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

    Receive News & Ratings for Amgen Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Amgen and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Scott Capital Advisors LLC Buys Shares of 6,382 Bank of America Co. (NYSE:BAC)

    Scott Capital Advisors LLC Buys Shares of 6,382 Bank of America Co. (NYSE:BAC)

    [ad_1]

    Scott Capital Advisors LLC bought a new stake in Bank of America Co. (NYSE:BAC) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 6,382 shares of the financial services provider’s stock, valued at approximately $211,000.

    Several other hedge funds have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its stake in Bank of America by 0.6% in the third quarter. Vanguard Group Inc. now owns 602,457,736 shares of the financial services provider’s stock valued at $18,194,222,000 after buying an additional 3,313,229 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in Bank of America by 60.0% in the third quarter. Price T Rowe Associates Inc. MD now owns 103,645,596 shares of the financial services provider’s stock valued at $3,130,177,000 after buying an additional 38,870,780 shares during the period. Legal & General Group Plc raised its position in shares of Bank of America by 2.9% during the second quarter. Legal & General Group Plc now owns 52,475,574 shares of the financial services provider’s stock worth $1,633,568,000 after purchasing an additional 1,493,089 shares during the period. Dodge & Cox raised its position in shares of Bank of America by 3.5% during the second quarter. Dodge & Cox now owns 44,434,589 shares of the financial services provider’s stock worth $1,383,249,000 after purchasing an additional 1,511,600 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Bank of America by 1.7% during the first quarter. Charles Schwab Investment Management Inc. now owns 36,940,776 shares of the financial services provider’s stock worth $1,522,699,000 after purchasing an additional 603,512 shares during the period. Institutional investors and hedge funds own 68.34% of the company’s stock.

    Wall Street Analysts Forecast Growth

    A number of equities research analysts have recently commented on the company. Piper Sandler lowered Bank of America from a “neutral” rating to an “underweight” rating and dropped their price target for the stock from $36.00 to $33.00 in a research report on Tuesday, January 17th. Royal Bank of Canada dropped their price target on Bank of America from $40.00 to $34.00 and set an “outperform” rating on the stock in a research report on Friday. Citigroup raised their price target on Bank of America from $36.00 to $38.00 in a research report on Tuesday, January 17th. StockNews.com assumed coverage on Bank of America in a research report on Thursday, March 16th. They set a “hold” rating on the stock. Finally, Atlantic Securities lowered Bank of America from an “overweight” rating to a “neutral” rating and set a $40.00 price target on the stock. in a research report on Tuesday, January 31st. Two analysts have rated the stock with a sell rating, seven have given a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, Bank of America has an average rating of “Hold” and an average target price of $39.28.

    Bank of America Stock Up 0.6 %

    BAC stock opened at $27.14 on Friday. The company has a quick ratio of 0.77, a current ratio of 0.78 and a debt-to-equity ratio of 1.13. The business has a 50 day moving average price of $33.34 and a two-hundred day moving average price of $33.87. The company has a market cap of $217.22 billion, a price-to-earnings ratio of 8.51, a P/E/G ratio of 1.14 and a beta of 1.40. Bank of America Co. has a twelve month low of $26.32 and a twelve month high of $44.39.

    Bank of America (NYSE:BAC – Get Rating) last posted its quarterly earnings results on Friday, January 13th. The financial services provider reported $0.85 earnings per share for the quarter, beating analysts’ consensus estimates of $0.76 by $0.09. The firm had revenue of $24.50 billion during the quarter, compared to the consensus estimate of $24.17 billion. Bank of America had a return on equity of 11.41% and a net margin of 23.93%. The business’s revenue was up 11.1% compared to the same quarter last year. During the same period last year, the company earned $0.82 earnings per share. Analysts anticipate that Bank of America Co. will post 3.37 EPS for the current fiscal year.

    Bank of America Dividend Announcement

    The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 31st. Stockholders of record on Friday, March 3rd will be given a $0.22 dividend. The ex-dividend date is Thursday, March 2nd. This represents a $0.88 dividend on an annualized basis and a dividend yield of 3.24%. Bank of America’s payout ratio is 27.59%.

    Insider Activity

    In other news, insider Matthew M. Koder sold 214,745 shares of the firm’s stock in a transaction that occurred on Thursday, February 2nd. The stock was sold at an average price of $35.91, for a total value of $7,711,492.95. Following the completion of the sale, the insider now directly owns 214,747 shares of the company’s stock, valued at $7,711,564.77. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, insider Matthew M. Koder sold 214,745 shares of the firm’s stock in a transaction that occurred on Thursday, February 2nd. The stock was sold at an average price of $35.91, for a total value of $7,711,492.95. Following the completion of the sale, the insider now directly owns 214,747 shares of the company’s stock, valued at $7,711,564.77. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Matthew M. Koder sold 105,054 shares of the firm’s stock in a transaction that occurred on Thursday, February 23rd. The shares were sold at an average price of $34.27, for a total value of $3,600,200.58. Following the completion of the sale, the insider now directly owns 319,803 shares of the company’s stock, valued at $10,959,648.81. The disclosure for this sale can be found here. Insiders own 0.27% of the company’s stock.

    Bank of America Profile

    (Get Rating)

    Bank of America Corp. is a bank and financial holding company, which engages in the provision of banking and nonbank financial services. It operates through the following segments: Consumer Banking, Global Wealth and Investment Management (GWIM), Global Banking, Global Markets, and All Other. The Consumer Banking segment offers credit, banking, and investment products and services to consumers and small businesses.

    Read More

    Want to see what other hedge funds are holding BAC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bank of America Co. (NYSE:BAC – Get Rating).

    Institutional Ownership by Quarter for Bank of America (NYSE:BAC)

    Receive News & Ratings for Bank of America Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bank of America and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Congress Asset Management Co. MA Buys 22,611 Shares of Cisco Systems, Inc. (NASDAQ:CSCO)

    Congress Asset Management Co. MA Buys 22,611 Shares of Cisco Systems, Inc. (NASDAQ:CSCO)

    [ad_1]

    Congress Asset Management Co. MA grew its stake in Cisco Systems, Inc. (NASDAQ:CSCO – Get Rating) by 8.9% during the 4th quarter, HoldingsChannel reports. The firm owned 275,317 shares of the network equipment provider’s stock after acquiring an additional 22,611 shares during the quarter. Congress Asset Management Co. MA’s holdings in Cisco Systems were worth $13,116,000 at the end of the most recent reporting period.

    Several other large investors also recently modified their holdings of CSCO. United Bank bought a new stake in shares of Cisco Systems in the 1st quarter valued at approximately $645,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Cisco Systems by 32.5% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,243,073 shares of the network equipment provider’s stock valued at $236,593,000 after purchasing an additional 1,040,607 shares during the period. Roundview Capital LLC grew its position in Cisco Systems by 13.1% during the 1st quarter. Roundview Capital LLC now owns 10,540 shares of the network equipment provider’s stock worth $588,000 after acquiring an additional 1,221 shares during the last quarter. Merit Financial Group LLC grew its position in Cisco Systems by 21.5% during the 1st quarter. Merit Financial Group LLC now owns 11,763 shares of the network equipment provider’s stock worth $656,000 after acquiring an additional 2,079 shares during the last quarter. Finally, Mackenzie Financial Corp grew its position in Cisco Systems by 8.1% during the 1st quarter. Mackenzie Financial Corp now owns 2,429,518 shares of the network equipment provider’s stock worth $135,470,000 after acquiring an additional 182,857 shares during the last quarter. 71.10% of the stock is currently owned by institutional investors.

    Insiders Place Their Bets

    In other news, EVP Deborah L. Stahlkopf sold 23,701 shares of the firm’s stock in a transaction dated Friday, February 17th. The stock was sold at an average price of $50.90, for a total value of $1,206,380.90. Following the completion of the transaction, the executive vice president now owns 184,853 shares in the company, valued at approximately $9,409,017.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, EVP Deborah L. Stahlkopf sold 23,701 shares of the firm’s stock in a transaction dated Friday, February 17th. The stock was sold at an average price of $50.90, for a total value of $1,206,380.90. Following the completion of the transaction, the executive vice president now owns 184,853 shares in the company, valued at approximately $9,409,017.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Deborah L. Stahlkopf sold 3,142 shares of the firm’s stock in a transaction dated Tuesday, March 14th. The shares were sold at an average price of $48.78, for a total value of $153,266.76. Following the completion of the transaction, the executive vice president now owns 180,697 shares of the company’s stock, valued at approximately $8,814,399.66. The disclosure for this sale can be found here. In the last 90 days, insiders sold 47,568 shares of company stock worth $2,376,624. Corporate insiders own 0.02% of the company’s stock.

    Cisco Systems Price Performance

    CSCO stock opened at $50.51 on Friday. The stock has a 50-day moving average price of $48.73 and a two-hundred day moving average price of $46.51. The stock has a market cap of $206.88 billion, a PE ratio of 18.50, a price-to-earnings-growth ratio of 2.28 and a beta of 1.00. The company has a current ratio of 1.41, a quick ratio of 1.30 and a debt-to-equity ratio of 0.18. Cisco Systems, Inc. has a 1 year low of $38.60 and a 1 year high of $56.94.

    Cisco Systems (NASDAQ:CSCO – Get Rating) last released its earnings results on Wednesday, February 15th. The network equipment provider reported $0.88 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.76 by $0.12. The firm had revenue of $13.59 billion during the quarter, compared to analysts’ expectations of $13.41 billion. Cisco Systems had a return on equity of 31.19% and a net margin of 21.26%. The company’s revenue was up 6.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.77 EPS. Equities analysts forecast that Cisco Systems, Inc. will post 3.34 EPS for the current fiscal year.

    Cisco Systems Increases Dividend

    The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 26th. Shareholders of record on Wednesday, April 5th will be issued a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 3.09%. The ex-dividend date is Tuesday, April 4th. This is a boost from Cisco Systems’s previous quarterly dividend of $0.38. Cisco Systems’s dividend payout ratio is 55.68%.

    Wall Street Analysts Forecast Growth

    A number of equities research analysts recently commented on the company. UBS Group increased their price target on Cisco Systems from $48.00 to $51.00 and gave the stock a “neutral” rating in a research report on Thursday, February 16th. The Goldman Sachs Group assumed coverage on Cisco Systems in a research report on Monday, March 6th. They set a “neutral” rating on the stock. JPMorgan Chase & Co. increased their price target on Cisco Systems from $54.00 to $55.00 and gave the stock a “neutral” rating in a research report on Thursday, February 16th. Raymond James increased their price target on Cisco Systems from $59.00 to $63.00 and gave the stock an “outperform” rating in a research report on Thursday, February 16th. Finally, Loop Capital upped their price objective on Cisco Systems from $65.00 to $66.00 and gave the stock a “buy” rating in a report on Thursday, February 16th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Cisco Systems currently has a consensus rating of “Moderate Buy” and a consensus target price of $56.38.

    Cisco Systems Profile

    (Get Rating)

    Cisco Systems, Inc engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Switches, Routers, Wireless, Network Management Interfaces and Modules, Optical Networking, Access Points, Outdoor and Industrial Access Points, Next-Generation Firewalls, Advanced Malware Protection, VPN Security Clients, Email, and Web Security.

    Recommended Stories

    Want to see what other hedge funds are holding CSCO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cisco Systems, Inc. (NASDAQ:CSCO – Get Rating).

    Institutional Ownership by Quarter for Cisco Systems (NASDAQ:CSCO)

    Receive News & Ratings for Cisco Systems Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Cisco Systems and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Stillwater Capital Advisors LLC Raises Stake in Vanguard FTSE Developed Markets ETF (NYSEARCA:VEA)

    Stillwater Capital Advisors LLC Raises Stake in Vanguard FTSE Developed Markets ETF (NYSEARCA:VEA)

    [ad_1]

    Stillwater Capital Advisors LLC raised its stake in Vanguard FTSE Developed Markets ETF (NYSEARCA:VEA – Get Rating) by 1.0% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 52,136 shares of the company’s stock after buying an additional 516 shares during the quarter. Stillwater Capital Advisors LLC’s holdings in Vanguard FTSE Developed Markets ETF were worth $2,188,000 at the end of the most recent quarter.

    Other large investors also recently added to or reduced their stakes in the company. Glassy Mountain Advisors Inc. purchased a new position in shares of Vanguard FTSE Developed Markets ETF during the 4th quarter worth $27,000. Wolff Wiese Magana LLC grew its holdings in shares of Vanguard FTSE Developed Markets ETF by 240.3% during the 3rd quarter. Wolff Wiese Magana LLC now owns 878 shares of the company’s stock worth $32,000 after purchasing an additional 620 shares during the period. Toth Financial Advisory Corp grew its holdings in shares of Vanguard FTSE Developed Markets ETF by 300.9% during the 3rd quarter. Toth Financial Advisory Corp now owns 882 shares of the company’s stock worth $32,000 after purchasing an additional 662 shares during the period. Northwest Investment Counselors LLC purchased a new position in shares of Vanguard FTSE Developed Markets ETF during the 3rd quarter worth $34,000. Finally, Legend Financial Advisors Inc. purchased a new position in shares of Vanguard FTSE Developed Markets ETF during the 3rd quarter worth $35,000.

    Vanguard FTSE Developed Markets ETF Price Performance

    Shares of Vanguard FTSE Developed Markets ETF stock opened at $43.76 on Wednesday. The business has a 50-day moving average of $44.82 and a 200 day moving average of $41.93. Vanguard FTSE Developed Markets ETF has a 12 month low of $35.42 and a 12 month high of $49.06. The stock has a market capitalization of $104.59 billion, a price-to-earnings ratio of 11.40 and a beta of 0.89.

    About Vanguard FTSE Developed Markets ETF

    (Get Rating)

    The Vanguard Developed Markets Index Fund (VEA) is an exchange-traded fund that mostly invests in total market equity. The fund tracks a market-cap weighted index of large-, mid- and small-cap stocks from developed markets outside the US. VEA was launched on Jul 20, 2007 and is managed by Vanguard.

    Featured Articles

    Institutional Ownership by Quarter for Vanguard FTSE Developed Markets ETF (NYSEARCA:VEA)

    Receive News & Ratings for Vanguard FTSE Developed Markets ETF Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Vanguard FTSE Developed Markets ETF and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • Cisco Systems, Inc. (NASDAQ:CSCO) Shares Sold by Addenda Capital Inc.

    Cisco Systems, Inc. (NASDAQ:CSCO) Shares Sold by Addenda Capital Inc.

    [ad_1]

    Addenda Capital Inc. lessened its holdings in Cisco Systems, Inc. (NASDAQ:CSCO – Get Rating) by 1.3% in the fourth quarter, HoldingsChannel.com reports. The firm owned 119,695 shares of the network equipment provider’s stock after selling 1,554 shares during the period. Addenda Capital Inc.’s holdings in Cisco Systems were worth $5,703,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

    A number of other hedge funds have also recently added to or reduced their stakes in the business. Smith Chas P & Associates PA Cpas boosted its holdings in Cisco Systems by 1.5% in the fourth quarter. Smith Chas P & Associates PA Cpas now owns 1,008,481 shares of the network equipment provider’s stock worth $48,044,000 after purchasing an additional 15,109 shares during the period. Bremer Bank National Association boosted its holdings in shares of Cisco Systems by 54.1% during the fourth quarter. Bremer Bank National Association now owns 53,547 shares of the network equipment provider’s stock valued at $2,551,000 after acquiring an additional 18,806 shares during the period. KMG Fiduciary Partners LLC boosted its holdings in shares of Cisco Systems by 5.0% during the fourth quarter. KMG Fiduciary Partners LLC now owns 81,825 shares of the network equipment provider’s stock valued at $3,898,000 after acquiring an additional 3,903 shares during the period. Bath Savings Trust Co boosted its holdings in shares of Cisco Systems by 1.5% during the fourth quarter. Bath Savings Trust Co now owns 21,643 shares of the network equipment provider’s stock valued at $1,031,000 after acquiring an additional 323 shares during the period. Finally, Pacifica Partners Inc. boosted its holdings in shares of Cisco Systems by 4.0% during the fourth quarter. Pacifica Partners Inc. now owns 34,145 shares of the network equipment provider’s stock valued at $1,625,000 after acquiring an additional 1,323 shares during the period. Institutional investors and hedge funds own 71.10% of the company’s stock.

    Cisco Systems Price Performance

    Shares of Cisco Systems stock opened at $50.94 on Tuesday. The company’s 50-day moving average price is $48.64 and its two-hundred day moving average price is $46.38. The company has a current ratio of 1.41, a quick ratio of 1.30 and a debt-to-equity ratio of 0.18. The stock has a market cap of $208.64 billion, a PE ratio of 18.66, a price-to-earnings-growth ratio of 2.31 and a beta of 1.00. Cisco Systems, Inc. has a 52 week low of $38.60 and a 52 week high of $56.94.

    Cisco Systems (NASDAQ:CSCO – Get Rating) last posted its quarterly earnings data on Wednesday, February 15th. The network equipment provider reported $0.88 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.76 by $0.12. The firm had revenue of $13.59 billion for the quarter, compared to the consensus estimate of $13.41 billion. Cisco Systems had a return on equity of 31.19% and a net margin of 21.26%. The business’s revenue for the quarter was up 6.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.77 EPS. As a group, sell-side analysts anticipate that Cisco Systems, Inc. will post 3.34 EPS for the current fiscal year.

    Cisco Systems Increases Dividend

    The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 26th. Shareholders of record on Wednesday, April 5th will be issued a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 3.06%. The ex-dividend date is Tuesday, April 4th. This is an increase from Cisco Systems’s previous quarterly dividend of $0.38. Cisco Systems’s payout ratio is presently 55.68%.

    Insiders Place Their Bets

    In other Cisco Systems news, EVP Deborah L. Stahlkopf sold 23,701 shares of the business’s stock in a transaction dated Friday, February 17th. The stock was sold at an average price of $50.90, for a total transaction of $1,206,380.90. Following the sale, the executive vice president now owns 184,853 shares in the company, valued at approximately $9,409,017.70. The transaction was disclosed in a filing with the SEC, which is available through this link. In other Cisco Systems news, CEO Charles Robbins sold 20,117 shares of Cisco Systems stock in a transaction dated Thursday, February 23rd. The stock was sold at an average price of $49.08, for a total transaction of $987,342.36. Following the transaction, the chief executive officer now owns 798,970 shares of the company’s stock, valued at approximately $39,213,447.60. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Deborah L. Stahlkopf sold 23,701 shares of Cisco Systems stock in a transaction dated Friday, February 17th. The shares were sold at an average price of $50.90, for a total value of $1,206,380.90. Following the transaction, the executive vice president now directly owns 184,853 shares in the company, valued at approximately $9,409,017.70. The disclosure for this sale can be found here. In the last quarter, insiders have sold 47,568 shares of company stock worth $2,376,624. Company insiders own 0.02% of the company’s stock.

    Wall Street Analysts Forecast Growth

    Several equities analysts have recently issued reports on CSCO shares. Wells Fargo & Company boosted their price target on shares of Cisco Systems from $52.00 to $57.00 and gave the company an “equal weight” rating in a report on Thursday, February 16th. Deutsche Bank Aktiengesellschaft boosted their price target on shares of Cisco Systems from $52.00 to $55.00 and gave the company a “hold” rating in a report on Wednesday, February 22nd. Tigress Financial restated a “buy” rating and set a $73.00 price objective on shares of Cisco Systems in a research note on Friday. Piper Sandler lifted their price objective on shares of Cisco Systems from $49.00 to $53.00 and gave the company a “neutral” rating in a research note on Thursday, February 16th. Finally, Cowen lifted their price objective on shares of Cisco Systems from $61.00 to $64.00 and gave the company an “outperform” rating in a research note on Thursday, February 16th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Cisco Systems has a consensus rating of “Moderate Buy” and a consensus price target of $56.38.

    About Cisco Systems

    (Get Rating)

    Cisco Systems, Inc engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Switches, Routers, Wireless, Network Management Interfaces and Modules, Optical Networking, Access Points, Outdoor and Industrial Access Points, Next-Generation Firewalls, Advanced Malware Protection, VPN Security Clients, Email, and Web Security.

    Recommended Stories

    Want to see what other hedge funds are holding CSCO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cisco Systems, Inc. (NASDAQ:CSCO – Get Rating).

    Institutional Ownership by Quarter for Cisco Systems (NASDAQ:CSCO)

    Receive News & Ratings for Cisco Systems Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Cisco Systems and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • 23,470 Shares in Meta Platforms, Inc. (NASDAQ:META) Bought by Accuvest Global Advisors

    23,470 Shares in Meta Platforms, Inc. (NASDAQ:META) Bought by Accuvest Global Advisors

    [ad_1]

    Accuvest Global Advisors bought a new position in Meta Platforms, Inc. (NASDAQ:META – Get Rating) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 23,470 shares of the social networking company’s stock, valued at approximately $2,824,000. Meta Platforms accounts for approximately 0.9% of Accuvest Global Advisors’ holdings, making the stock its 27th biggest position.

    Several other large investors have also made changes to their positions in the company. Charles Schwab Investment Management Inc. raised its position in shares of Meta Platforms by 1.1% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 11,830,209 shares of the social networking company’s stock worth $2,630,566,000 after buying an additional 128,126 shares during the period. DNB Asset Management AS purchased a new position in shares of Meta Platforms in the 4th quarter worth $401,963,000. Renaissance Technologies LLC raised its position in shares of Meta Platforms by 310.7% in the 1st quarter. Renaissance Technologies LLC now owns 3,001,000 shares of the social networking company’s stock worth $667,302,000 after buying an additional 2,270,300 shares during the period. Ruane Cunniff & Goldfarb L.P. raised its position in shares of Meta Platforms by 7.2% in the 1st quarter. Ruane Cunniff & Goldfarb L.P. now owns 2,834,735 shares of the social networking company’s stock worth $630,332,000 after buying an additional 189,688 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in shares of Meta Platforms by 12.5% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,244,201 shares of the social networking company’s stock worth $499,020,000 after buying an additional 249,926 shares during the period. 60.92% of the stock is owned by hedge funds and other institutional investors.

    Insider Transactions at Meta Platforms

    In other news, CAO Susan J.S. Taylor sold 1,400 shares of the business’s stock in a transaction that occurred on Thursday, February 16th. The stock was sold at an average price of $172.96, for a total transaction of $242,144.00. Following the completion of the transaction, the chief accounting officer now directly owns 2,949 shares in the company, valued at $510,059.04. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CTO Andrew Bosworth sold 10,888 shares of the business’s stock in a transaction that occurred on Wednesday, February 15th. The stock was sold at an average price of $179.48, for a total transaction of $1,954,178.24. Following the sale, the chief technology officer now owns 12,743 shares of the company’s stock, valued at $2,287,113.64. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CAO Susan J.S. Taylor sold 1,400 shares of the business’s stock in a transaction that occurred on Thursday, February 16th. The stock was sold at an average price of $172.96, for a total value of $242,144.00. Following the sale, the chief accounting officer now directly owns 2,949 shares in the company, valued at approximately $510,059.04. The disclosure for this sale can be found here. Over the last three months, insiders sold 68,342 shares of company stock worth $12,285,012. Company insiders own 14.03% of the company’s stock.

    Wall Street Analyst Weigh In

    Several research analysts have commented on the company. HSBC lowered Meta Platforms from a “hold” rating to a “reduce” rating and set a $110.00 price objective on the stock. in a research report on Friday, February 3rd. Rosenblatt Securities raised Meta Platforms from a “neutral” rating to a “buy” rating and raised their price objective for the company from $104.00 to $220.00 in a research report on Thursday, February 2nd. Wells Fargo & Company raised their price objective on Meta Platforms from $250.00 to $280.00 in a research report on Thursday. Oppenheimer raised their price objective on Meta Platforms from $235.00 to $260.00 and gave the company an “outperform” rating in a research report on Wednesday, March 15th. Finally, Morgan Stanley raised their price objective on Meta Platforms from $130.00 to $190.00 and gave the company an “equal weight” rating in a research report on Thursday, February 2nd. Four analysts have rated the stock with a sell rating, eight have given a hold rating, thirty-seven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $209.94.

    Meta Platforms Stock Performance

    Shares of NASDAQ META opened at $195.61 on Monday. The company has a current ratio of 2.20, a quick ratio of 2.20 and a debt-to-equity ratio of 0.08. The stock has a 50 day simple moving average of $166.42 and a 200-day simple moving average of $140.06. The company has a market cap of $507.15 billion, a PE ratio of 22.80, a P/E/G ratio of 1.78 and a beta of 1.18. Meta Platforms, Inc. has a 12-month low of $88.09 and a 12-month high of $236.86.

    Meta Platforms (NASDAQ:META – Get Rating) last issued its quarterly earnings data on Wednesday, February 1st. The social networking company reported $3.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.12 by $0.88. The business had revenue of $32.17 billion during the quarter, compared to the consensus estimate of $31.69 billion. Meta Platforms had a return on equity of 21.23% and a net margin of 19.90%. The business’s revenue was down 4.5% on a year-over-year basis. During the same period in the previous year, the firm posted $3.67 earnings per share. On average, equities research analysts forecast that Meta Platforms, Inc. will post 10.38 EPS for the current year.

    Meta Platforms Profile

    (Get Rating)

    Meta Platforms, Inc, engages in the development of social media applications. It builds technology that helps people connect, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services.

    Featured Stories

    Want to see what other hedge funds are holding META? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Meta Platforms, Inc. (NASDAQ:META – Get Rating).

    Institutional Ownership by Quarter for Meta Platforms (NASDAQ:META)

    Receive News & Ratings for Meta Platforms Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Meta Platforms and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link

  • M&R Capital Management Inc. Sells 250 Shares of NVIDIA Co. (NASDAQ:NVDA)

    M&R Capital Management Inc. Sells 250 Shares of NVIDIA Co. (NASDAQ:NVDA)

    [ad_1]

    M&R Capital Management Inc. lowered its stake in NVIDIA Co. (NASDAQ:NVDA – Get Rating) by 18.5% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 1,105 shares of the computer hardware maker’s stock after selling 250 shares during the quarter. M&R Capital Management Inc.’s holdings in NVIDIA were worth $161,000 at the end of the most recent quarter.

    Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Vanguard Group Inc. lifted its position in NVIDIA by 1.2% in the third quarter. Vanguard Group Inc. now owns 203,747,246 shares of the computer hardware maker’s stock valued at $24,732,878,000 after purchasing an additional 2,326,387 shares during the last quarter. State Street Corp lifted its position in NVIDIA by 0.9% in the third quarter. State Street Corp now owns 98,751,264 shares of the computer hardware maker’s stock valued at $11,987,416,000 after purchasing an additional 908,481 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in NVIDIA by 7.2% in the second quarter. Price T Rowe Associates Inc. MD now owns 56,929,819 shares of the computer hardware maker’s stock valued at $8,629,991,000 after purchasing an additional 3,813,087 shares during the last quarter. Legal & General Group Plc lifted its position in NVIDIA by 4.4% in the second quarter. Legal & General Group Plc now owns 18,243,948 shares of the computer hardware maker’s stock valued at $2,765,602,000 after purchasing an additional 764,184 shares during the last quarter. Finally, UBS Asset Management Americas Inc. lifted its position in NVIDIA by 3.3% in the second quarter. UBS Asset Management Americas Inc. now owns 14,612,261 shares of the computer hardware maker’s stock valued at $2,215,073,000 after purchasing an additional 467,060 shares during the last quarter. Institutional investors own 61.80% of the company’s stock.

    Insider Activity

    In other news, Director John Dabiri sold 293 shares of the company’s stock in a transaction on Monday, December 19th. The stock was sold at an average price of $165.80, for a total transaction of $48,579.40. Following the transaction, the director now directly owns 2,417 shares of the company’s stock, valued at $400,738.60. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other NVIDIA news, Director John Dabiri sold 293 shares of the stock in a transaction dated Monday, December 19th. The stock was sold at an average price of $165.80, for a total value of $48,579.40. Following the transaction, the director now owns 2,417 shares of the company’s stock, valued at $400,738.60. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Mark L. Perry sold 20,000 shares of the stock in a transaction dated Monday, February 27th. The shares were sold at an average price of $236.37, for a total value of $4,727,400.00. Following the completion of the transaction, the director now directly owns 140,000 shares in the company, valued at approximately $33,091,800. The disclosure for this sale can be found here. Insiders have sold a total of 293,066 shares of company stock valued at $51,229,679 over the last ninety days. 4.04% of the stock is currently owned by corporate insiders.

    NVIDIA Trading Up 0.7 %

    Shares of NASDAQ:NVDA opened at $257.25 on Friday. The company has a market cap of $635.41 billion, a P/E ratio of 147.84, a PEG ratio of 4.53 and a beta of 1.76. The company has a debt-to-equity ratio of 0.44, a current ratio of 3.52 and a quick ratio of 2.73. NVIDIA Co. has a 1 year low of $108.13 and a 1 year high of $289.46. The stock’s fifty day moving average price is $210.84 and its 200-day moving average price is $167.00.

    NVIDIA (NASDAQ:NVDA – Get Rating) last announced its quarterly earnings results on Wednesday, February 22nd. The computer hardware maker reported $0.88 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.81 by $0.07. The firm had revenue of $6.05 billion for the quarter, compared to the consensus estimate of $6.02 billion. NVIDIA had a return on equity of 26.61% and a net margin of 16.19%. The company’s quarterly revenue was down 20.8% on a year-over-year basis. During the same period in the prior year, the company posted $1.14 earnings per share. Sell-side analysts expect that NVIDIA Co. will post 3.21 earnings per share for the current year.

    NVIDIA Dividend Announcement

    The firm also recently declared a quarterly dividend, which will be paid on Wednesday, March 29th. Stockholders of record on Wednesday, March 8th will be issued a dividend of $0.04 per share. This represents a $0.16 dividend on an annualized basis and a dividend yield of 0.06%. The ex-dividend date is Tuesday, March 7th. NVIDIA’s payout ratio is currently 9.20%.

    Wall Street Analysts Forecast Growth

    Several equities analysts have recently issued reports on NVDA shares. StockNews.com started coverage on NVIDIA in a research note on Thursday. They set a “hold” rating on the stock. Raymond James reissued a “strong-buy” rating and set a $290.00 target price on shares of NVIDIA in a research note on Thursday, March 2nd. Cowen boosted their target price on NVIDIA from $200.00 to $220.00 in a research note on Monday, December 12th. Jefferies Financial Group boosted their target price on NVIDIA from $275.00 to $300.00 and gave the company a “buy” rating in a research note on Thursday, February 23rd. Finally, BMO Capital Markets boosted their target price on NVIDIA from $210.00 to $240.00 and gave the company an “outperform” rating in a research note on Tuesday, February 21st. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating, twenty-six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $245.32.

    NVIDIA Profile

    (Get Rating)

    NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU), Tegra Processor, and All Other. The GPU segment consists of product brands, including GeForce for gamers, Quadro for designers, Tesla and DGX for AI data scientists and big data researchers, and GRID for cloud-based visual computing users.

    See Also

    Want to see what other hedge funds are holding NVDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NVIDIA Co. (NASDAQ:NVDA – Get Rating).

    Institutional Ownership by Quarter for NVIDIA (NASDAQ:NVDA)

    Receive News & Ratings for NVIDIA Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NVIDIA and related companies with MarketBeat.com’s FREE daily email newsletter.

    [ad_2]

    ABMN Staff

    Source link